Furthermore, ICIs have the potential to trigger immune-related endocrine diseases in tumor patients, such as thyroid and pituitary dysfunction, and these complications are relatively more frequent than expected (e.g., 11.8% in anti-PD-1 treatment, 13.4% in anti-PD-L1 treatment, 5% in anti-CTLA4 treatment, and 18.5% in sequential and/or combination treatment) [16–19]. Here, CD274 is linked to neoplasm.